Management of Supraventricular Tachycardia (SVT) in Patients on Flecainide
Assessment and Immediate Management
- Flecainide, a Class IC antiarrhythmic agent, can cause significant bradycardia as a side effect, especially at higher doses, according to the American Heart Association 1, 2
- Reducing the dose of flecainide is the first intervention to address bradycardia, as recommended by the American College of Cardiology 3
Alternative Treatment Options
- Electrophysiological (EP) study with catheter ablation is the definitive treatment for SVT and should be strongly considered, especially given the medication side effect, as stated by the American Heart Association 1, 4, 5
- Oral beta blockers, diltiazem, or verapamil can be considered as alternative pharmacological options if the patient is not a candidate for ablation, according to the American College of Cardiology 1, 5, 7
Long-term Management Considerations
- Beta blockers are first-line agents with fewer conduction effects than flecainide, as recommended by the American Heart Association 5
- Calcium channel blockers (diltiazem or verapamil) are effective alternatives with Class I recommendation, according to the American College of Cardiology 1, 5
- For patients who cannot tolerate any of these medications, sotalol or dofetilide may be reasonable alternatives, though they require careful monitoring, as stated by the American Heart Association 1, 3, 8
Monitoring and Follow-up
- Teach patients to perform vagal maneuvers as a non-pharmacological method to terminate acute SVT episodes, as recommended by the American Heart Association 1, 4, 5
- Patients with bradycardia on flecainide should avoid situations that further lower heart rate (e.g., extreme vagal maneuvers) until the medication is adjusted, according to the American College of Cardiology 5, 6